# Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer

> **NCT00296062** · PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Colorectal Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** irinotecan hydrochloride
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00296062
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2009-10
- **Final completion:** 2011-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Trial did not move to Phase II portion due to poor tolerance of treatment
- **Last updated:** 2012-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00296062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00296062, "Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00296062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*